KEYNOTE-042 expanded the inclusion criterion to PD-L1 tumor cell proportion score (TPS) ≥ 1%, and the results suggested that pembrolizumab significantly reduced the risk of death by 19% compared with chemotherapy. Here, CD274 is linked to neoplasm.